24 VS 48-WEEK TREATMENT WITH PEG-IFN ALPHA-2A IN PATIENTS WITH GENOTYPE 2/3 CHRONIC HEPATITIS C

This study has been withdrawn prior to enrollment.
(Time elapsed to require permissions and a recent paper showed a high efficacy of a 48-week regimen in this setting. It seems non-ethical to start this trial)
Sponsor:
Information provided by (Responsible Party):
Prof. Guglielmo Borgia, Federico II University
ClinicalTrials.gov Identifier:
NCT01517308
First received: January 17, 2012
Last updated: March 16, 2012
Last verified: March 2012
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Estimated Study Completion Date: November 2015
  Estimated Primary Completion Date: November 2015 (Final data collection date for primary outcome measure)